Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

Prostate Cancer and Prostatic Diseases volume 25, pages 373–374 (2022)Cite this article

Subjects

Recently, we read the paper of Cheng et al. [1] and the comment of Yang et al. [2] discussing the role of YAP1 in prostate cancer. Cheng et al. [1] agreed with the data of Lee et al. [3] indicating that an increase in YAP1 could be considered a biomarker for higher-grade prostate cancer. The authors also reported the loss of YAP1 in neuroendocrine prostate cancer (NEPC) [1]. Yang et al. provided an excellent supplement to this topic [2].

However, Lee’s paper [3] disagrees with the hypothesis proposed by Yang et al. that the androgen receptor (AR) can upregulate the expression of YAP1 [2]. The authors believe that AR can repress YAP1, and this is the mechanism by which enzalutamide (ENZA) increases YAP1 [3]. As Lee et al. demonstrated, ENZA suppressed the expression of AR, thereby relieving the inhibition of YAP1 by AR [3]. However, Abali et al. indicate that ENZA inhibited interactions between the YAP1 and AR proteins in LNCaP cells but failed to block their nuclear interactions in C4-2 cells [4]. They reported that YAP1 was a physiological binding partner and positive regulator of AR in prostate cancer [4]. However, Abali et al. proposed that YAP1 and AR interacted with each other and that YAP1 could enhance AR expression [4]. This does not mean that AR can positively regulate the expression of YAP1, as Yang et al. suggested [2]. Moreover, the hypothesis of Yang et al. still needs more evidence since no published paper supports it.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cheng S, Prieto-Dominguez N, Yang S, Connelly ZM, StPierre S, Rushing B, et al. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:661–9.

    Article  CAS  Google Scholar 

  2. Yang M, Li J, Li N, Guo H Re. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis. 2021. Epub ahead of print.

  3. Lee HC, Ou CH, Huang YC, Hou PC, Creighton CJ, Lin YS, et al. YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene. 2021;40:2407–21.

    Article  CAS  Google Scholar 

  4. Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B. YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Common 2015;1:8126.

  5. Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, et al. PARP inhibition suppresses GR-MYCN-CDK5-RB1-E2F1 signaling and neuroendocrine differentiation in castration-resistant prostate cancer. Clin Cancer Res. 2019;25:6839–51.

    Article  CAS  Google Scholar 

  6. Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158:171–84.

    Article  CAS  Google Scholar 

  7. Giordano F, Naimo GD, Nigro A, Romeo F, Paolì A, De Amicis F, et al. Valproic acid addresses neuroendocrine differentiation of LNCaP cells and maintains cell survival. Drug Des Devel Ther. 2019;13:4265–74.

    Article  CAS  Google Scholar 

  8. Dicken H, Hensley PJ, Kyprianou N. Prostate tumor neuroendocrine differentiation via EMT: the road less traveled. Asian J Urol. 2019;6:82–90.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology, Jianyang People Hospital, Jianyang, Sichuan, China

    Bo Peng, Yazheng Sun, Jie Wu & Qinglong Li

Authors
  1. Bo Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yazheng Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jie Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qinglong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Construction of the manuscript: QL; BP. Written of the manuscript: BP; YS. Modification of the manuscript: QL; JW.

Corresponding author

Correspondence to Qinglong Li.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peng, B., Sun, Y., Wu, J. et al. Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis 25, 373–374 (2022). https://doi.org/10.1038/s41391-021-00453-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-021-00453-x

Search

Advanced search

Quick links